Skip to main content

Table 3 Demographic data for study subjects

From: Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets

Sample Age (Range in yrs.) Diagnosis Duration (years) Current Meds Previous Treatments Past Med History
VL1009B 60–69 Vitiligo 10 None topical and oral steroid HTN
VL1010B 50–59 Vitiligo 2 None steroid (1.5 yrs ago) hypothyroid
VL1016Ba 70–79 Vitiligo 50 ASA, atenolol, lipitor, detrol LA Methoxsalen (45–50 yrs. ago), none currently None
VL1017Ba 30–39 Vitiligo 10 PABA, vitamin B12, trazodone and other antianxiety med light treatment (6 yrs. ago), Vit B12 injection None
VL1018Ba 30–39 Vitiligo 12 None None None
VL1019Ba 30–39 Vitiligo 26 None None Factor V disorder
VL1020B 60–69 Vitiligo 30 None None None
VL1021B 60–69 Vitiligo >20 sunblock benoquin (depigmentation agent) rosacea (10yrs ago), osteoarthritis, SCC (10yrs ago)
NL1001B 50–59 No disease none none none none
NL1004B 30–39 No disease none none none none
NL1013B 30–39 No disease none none none none
NL1014B 40–49 No disease none none none none
NL1020B 50–59 No disease none none none none
NL1032B 40–49 No disease none none none none
  1. Abbreviations: VL vitiligo, NL normal, B blood, PABA para amino benzoic acid, HTN hypertension, SCC squamous cell carcinoma, ASA amino salicylic acid, LA long acting. Patients were under no systemic or topical medications for 2 months prior to sampling. aStarred samples are shared between our previous skin and the present blood analyses. Gender and ethnicity details are withheld to protect patient privacy. While the healthy controls were 100% females, the female to male ratio in vitiligo patients is 6.2: 3.8. Ethnicity distribution among healthy controls is 67% African American, 17% Caucasian and 17% Asian and among VL patients 50% Caucasians, 25% Hispanics, 12.5% Asian and 12.5% African